drugset / Trial / NCT06243354
Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label phase 1/2 study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of HYP-2090PTSA in patients with advanced solid tumors harboring KRAS mutation and to determine the RP2D. In the dose expansion phase, preliminary efficacy and safety at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.
Timeline
- Start
- 2024-02-04
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HYP-2090PTSA | Unknown | 2.5 mg | Oral |
| Subject | HYP-2090PTSA | Unknown | 5 mg | Oral |
| Subject | HYP-2090PTSA | Unknown | 10 mg | Oral |
Indications
No indication recorded.